Innovation in AMR – the CARB-X Perspective

The spread of drug-resistant bacterial pathogens has been recognized as one of the largest global threats to mankind. In order to continue to benefit from the advancement of modern medicine, new treatment, prevention and diagnostic products are needed to satisfactorily treat or prevent infections. CARB-X is a global non-profit public-private partnership dedicated to accelerating antibacterial-related research to tackle the rising threat of drug-resistant bacteria. The CARB-X portfolio is the world's largest early development pipeline of new antibiotics, vaccines, rapid diagnostics and other products to prevent, diagnose and treat life-threatening bacterial infections. Since inception, three application rounds of funding have been completed with a significant worldwide response.